EyePoint Pharmaceuticals Reports Fiscal Period Ended December 31, 2018 Financial Results and Highlights Recent Clinical and Operational Developments

NEXT STORY
Rockwell Medical, Inc. Reports Fourth Quarter and Full Year 2018 Financial Results
PREV STORY
European Commission approves Roche’s Hemlibra for people with severe haemophilia A without factor VIII inhibitors
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Roche Annual General Meeting 2020: Voting will take place by independent proxy. Participation on site is neither possible nor permitted by Federal Council ordinance

author_avatar
NASDAQ Market News

Revelation Biosciences Inc. Announces Initiation of a Phase 2b Study to Assess Efficacy of Intranasal REVTx-99 for The Prevention of H3N2 Influenza

author_avatar
NASDAQ Market News

Grafix® Manuscript Reporting Positive Outcomes of Multicenter Chronic Complex Wounds with Exposed Tendon and Bone Clinical Trial is Available Electronically in Peer-Reviewed Journal

COLUMBIA, Md., Aug. 04, 2016 (GLOBE NEWSWIRE) -- Osiris Therapeutics, Inc. (NASDAQ:OSIR), a leading ...

author_avatar
NASDAQ Market News